---
title: "What will the FDA's decision be on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026?"
canonical_url: https://betcrypto.now/events/what-will-the-fdas-decision-be-on-anitocabtagene-autoleucel-anito-cel-by-gilead-sciences-in-2026
status: live
trading_closes_at: 2027-01-01T04:59:00+00:00
total_volume_usd: 3669.59
venues: ["Kalshi"]
categories: ["Markets"]
prices_as_of: 2026-10-09T08:22:42+00:00
publisher: BetCrypto
data_api: https://betcrypto.now/api/v1/events/what-will-the-fdas-decision-be-on-anitocabtagene-autoleucel-anito-cel-by-gilead-sciences-in-2026
---

# What will the FDA's decision be on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026?

Live · $3,670 traded · listed on Kalshi

## About

If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. 

Anitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in. It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma. In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.

_From Kalshi's listing._

## Main market

| Outcome | Probability | Cheapest | Kalshi |
|---|---|---|---|
| Yes | 91% | 94¢ on Kalshi | 94¢ |
| No | 10% | 13¢ on Kalshi | 13¢ |

## Open on a venue

- [Kalshi](https://betcrypto.now/go/e/2344?via=md)

---

Probability is the cross-venue consensus (book midpoints, 0–100%). Venue columns are what buying costs there (the ask). Prices move constantly; re-check at the canonical URL or https://betcrypto.now/api/v1/events/what-will-the-fdas-decision-be-on-anitocabtagene-autoleucel-anito-cel-by-gilead-sciences-in-2026.

BetCrypto is an odds-comparison and information service. It accepts no wagers and gives no betting or financial advice; prediction-market availability depends on where you live.